Modified kluyveromyces yeasts, their preparation and use

Human serum albumin, preparation and use

La présente invention concerne une préparation de sérum-albumine humaine ayant un indice de colorimétrie inférieur à 0,2, résultant de l'expression, dans un hôte eucaryote ou procaryote, d'une séquence d'ADN exogène.

HIGH-STABLE REKOMBINANTE YEASTS FOR THE PRODUCTION OF REKOMBINANTEN PROTEINS

YEAST WITH GEANDERTER PERMEABILITY

CHANGED KLUVEROMYCES YEAST YOUR PRODUCTION AND USE

YEAST PROMOTER AND ITS USE

ANTITHROMBOTIC POLYPEPTIDES AS ANTAGONISTS OF THE BINDING OF VWF TO PLATELETS OR TO SUBENDOTHELIUM

... 2126092 9315200 PCTABS00163 La présente invention concerne des polypeptides recombinants composés d'un partie adhésive dérivée de la structure du vWF capable d'antagoniser au moins partiellement la liaison du vWF aux plaquettes et/ou au sous-endothélium, et d'une partie permettant sa stabilisation et sa présentation in vivo, leur préparation et des compositions pharmaceutiques les contenant.

YEAST PROMOTER AND USE THEREOF

... 2113925 9304176 PCTABS00161 L'invention concerne des séquences d'ADN comprenant tout ou partie du promoteur du gène ADH4 de K.lactis ou d'un dérivé de celui-ci, et possédant une activité de promoteur transcriptionnel. Elle concerne également l'utilisation de ces séquences pour l'expression de gènes recombinés.

ALBUMIN DERIVATIVES WITH THERAPEUTIC FUNCTIONS

Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.

Yeast promoter and use thereof

The present invention concerns DNA sequences from the K. lactis PGK gene having transcriptional promoter activity, to expression vectors comprising these sequences and to their use for the production of proteins.

NEUARTIGE, BIOLOGISCH AKTIVE POLYPEPTIDE, IHRE HERSTELLUNG UND DIESE POLYPEPTIDE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG

Albumin-Derivate mit therapeutischer Funktion

ALBUMIN DERIVATIVES WITH THERAPEUTIC FUNCTION

MORE HEFEPROMOTER AND ITS USE

Yeast promoter and use thereof

Modified fungal cells and method for producing recombinant products

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAID POLYPEPTIDES

Novel biologically active polypeptides, preparation thereof and pharmaceutic al compositions containing said polypep-tides.

New polypeptides antithrombotic, their preparation and compositions pharmaceutical lescontenant

Recombinant polypeptides consisting of an adhesive portion derived from the structure of the vWF which is at least partially antagonistic to the bond between said vWF and the platelets and/or the subendothelium, as well as a portion for stabilising and presenting it in vivo; preparation thereof; and pharmaceutical compositions containing said polypeptides.

Yeast promoter and its use

L'invention concerne des séquences d'ADN comprenant tout ou partie du promoteur du gène ADH4 de K-lactis ou d'un dérivé de celui-ci, et possédant une activité de promoteur transcriptionnel. Elle concerne également l'utilisation de ces séquences pour l'expression de gènes recombinés. The invention relates to DNA sequences comprising all or part of the promoter of the K-lactis ADH4 gene or a derivative thereof, and having transcriptional promoter activity. It also relates to the use of these sequences for the expression of recombinant genes.

Methods of treatment with erythropoietin and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

HUMAN SERUM ALBUMIN, PRODUCTION AND USE

MODIFIED MUSHROOM CELLS AND METHOD TO HERSTELLLUNG REKOMBINANTER PRODUCTS

METHOD FOR THE PRODUCTION OF REKOMBINANTER PROTEINS AND BUT USED LANDLORD CELLS

NEW ONE, BIOLOGICAL ACTIVE POLYPEPTIDE, YOUR PRODUCTION AND THESE POLYPEPTIDE ABSTENTION PHARMACEUTICAL COMPOSITION

Modified fungal cells and method for producing recombinant products

MODIFIED FUNGAL CELLS AND METHOD FOR PRODUCING RECMODIFIED FUNGAL CELLS AND METHOD FOR PRODUCING RECOMBINANT PRODUCTS OMBINANT PRODUCTS

This invention relates to improved fungal cells and methods for producing recombinant products of improved quality and in high yields. More specifically, the present invention relates to fungal cells carrying specific modifications within their DNA sequences which cause them to exhibit at least a reduced capacity for O-glycosylating homologous and/or heterologous proteins, and the use of these cells as host cells to produce high yields of recombinant products.

Cloning vectors and/or expression preparation and use

L'invention concerne un nouveau plasmide de levure, de nouveaux vecteurs de clonage et/ou d'expression dérivés de celui-ci et leur utilisation.

Hormone and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

ALBUMIN DERIVATIVES WITH THERAPEUTIC FUNCTIONS

Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.

HEFE MIT GEANDERTER PERMEABILITÄT

HEFEPROMOTOR UND SEINE VERWENDUNG

HIGHLY STABLE RECOMBINANT YEASTS FOR THE PRODUCTION OF RECOMBINANT PROTEINS

... 2113551 9303159 PCTABS00161 La présente invention concerne de nouvelles levures recombinantes hautement stables en milieu complexe caractérisées en ce qu'il s'agit de levures du genre Kluyveromyces dans lesquelles un gène essentiel est non-fonctionnel, contenant un vecteur portant une copie fonctionnelle dudit gène.

MODIFIED FUNGAL CELLS AND METHOD FOR PRODUCING RECOMBINANT PRODUCTS

This invention relates to improved fungal cells and methods for producing recombinant products of improved quality and in high yields. More specifically, the present invention relates to fungal cells carrying specific modifications within their DNA sequences which cause them to exhibit at least a reduced capacity for O-glycosylating homologous and/or heterologous proteins, and the use of these cells as host cells to produce high yields of recombinant products.

MODIFIED KLUYVEROMYCES YEASTS, THEIR PREPARATION AND USE

... 2139117 9400579 PCTABS00165 La présente invention concerne des levures du genre Kluyveromyces présentant une ou plusieurs modifications génétiques d'au moins un gène codant pour une protéase, réduisant ou modifiant l'activité protéolytique desdites levures, ainsi que leur utilisation comme cellule hôte pour la sécrétion de protéines recombinantes.

New biologically active polypeptides, their pharmaceutical preparation and compositions lescontenant

Novel biologically active polypeptides, preparation thereof and pharmaceutical compositions containing said polypeptides.

Highly stable recombinant yeasts for the production of recombinant proteins, their preparation and their use

The present invention relates to new recombinant yeasts which are highly stable in complex medium, characterised in that they are yeasts of the Kluyveromyces genus in which an essential gene is non-functional, containing a vector carrying a functional copy of the said gene.

YEAST WITH MODIFIED PERMEABILITY

La présente invention se rapporte à une levure modifiée dans laquelle au mois deux des gènes contrôlant la perméabilité cellulaire de ladite levure sont modifiés, lesdites modifications ayant un effet additif ou synergique. Elle concerne également un procédé pour la préparer ainsi que ses utilisations.

HUMANES SERUM ALBUMIN, HERSTELLUNG UND VERWENDUNG

YEAST PROMOTER AND ITS USE

... 2108966 9219751 PCTABS00160 L'invention concerne des séquences d'ADN comprenant tout ou partie du promoteur du gène PGK de K.lactis, ou d'un dérivé de celui-ci, et possédant une activité de promoteur transcriptionnel. Elle concerne également l'utilisation de ces séquences pour l'expression de gènes recombinés.

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAID POLYPEPTIDES

New recombinant polypeptides (I) comprise an active portion derived from a therapeutically active polypeptide (II), genetically coupled to an albumin or albumin variant. Also claimed are: (1) a nucleotide sequence coding for (I); (2) an expression cassette comprising a sequence (1) under the control of a transcription initiation region and opt. a transcription termination region; (3) a self-replicating plasmid contg. a cassette (2); and (4) a recombinant eukaryotic or prokaryotic cell contg. a sequence (1), cassette (2) or plasmid (3).

PRODUCTION PROCESS FOR RECOMBINANT PROTEINS AND HOST CELLS USED

... 2110992 9301274 PCTABS00161 La présente invention concerne de nouvelles souches de levure du genre Kluyveromyces lactis modifiées par génie génétique, leur préparation, et leur utilisation pour la production de protéines recombinantes.

HUMAN SERUM-ALBUMIN, PREPARATION AND USE THEREOF

2126356 9315204 PCTABS00163 La présente invention concerne une préparation de sérum-albumine humaine ayant un indice de colorimétrie inférieur à 0,2, résultant de l'expression, dans un hôte eucaryote ou procaryote, d'une séquence d'ADN exogène. The present invention relates to a preparation of human serum albumin having a colorimetric index less than 0.2, resulting from the expression, in a eukaryotic or prokaryotic host, of an exogenous DNA sequence.

Yeast promoter and his use

L'invention concerne des séquences d'ADN comprenant tout ou partie du promoteur du gène PGK de K.lactis, ou d'un dérivé de celui-ci, et possédant une activité de promoteur transcriptionnel. Elle concerne également l'utilisation de ces séquences pour l'expression de gènes recombinés.

Process of production of recombining proteins and host cells used

La présente invention concerne de nouvelles souches de levure du genre Kluyveromyces lactis modifiées par génie génétique, leur préparation, et leur utilisation pour la production de protéines recombinantes. The present invention relates to novel strains of yeast of the genus Kluyveromyces lactis modified by genetic engineering, their preparation, and their use for the production of recombinant proteins.

METHODE ZUR HERSTELLUNG REKOMBINANTER PROTEINE UND DAFÜR VERWENDETE WIRTSZELLEN

HUMAN SERUM-ALBUMIN, PREPARATION AND USE THEREOF

La présente invention concerne une préparation de sé- rum-albumine humaine ayant un indice de colorimétrie infé- rieur à 0,2, résultant de l'expression, dans un hôte eucaryote ou procaryote, d'une séquence d'ADN exogène.

Kluyveromyces Yeasts, modified, preparation and use

Yeasts of the genus Kluyveromyces having one or more genetic modifications of at least one gene encoding a protease, said gene reducing or modifying the proteolytic activity of said yeasts. The invention also concerns the use of said yeasts as host cell for the secretion of recombinant proteins.

Insulin and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

METHOD FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM ALBUMIN AND OTHER HETEROLOGOUS PROTEINS FROM A YEAST

Serum-human albumin, preparation and utilization

MODIFIZIERTE PILZZELLEN UND METHODE ZUR HERSTELLLUNG REKOMBINANTER PRODUKTE

HEFE MIT GEANDERTER PERMEABILITÄT

Serum-human albumin, preparation and utilization

Methods of treatment with interferon and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

ALBUMIN DERIVATIVES WITH THERAPENUTIC FUNCTIONS

NEW MATERIAL: A hybrid macromolecule carrying active domain for virus receptor, active domain of molecue capable of binding to virus or active domain of ligand for receptor intervening in the pathological processes, wherein the active domain binds to albumin or albumin variant. USE: Drugs for treatment of viral infectious diseases or tumors, especially for treatment or prophylaxis of AIDS. PROCESS: A host microorganism (preferably yeast of Kluyveromyces) is transformed by a vector expressing the macromolecule as mentioned above (preferably an expression vector derived from a plasmid pKDI wherein the genes A, B and C, the origin of replication, and the inverse repeats have been conserved). The transformed host microorganism is cultivated to produce the objective macromolecule. COPYRIGHT: (C)1991,JPO ...

HOCHSTABILE REKOMBINANTE HEFEN FÜR DIE HERSTELLUNG VON REKOMBINANTEN PROTEINEN

NEW BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide a artificial protein having biological activity for use in pharmaceuticals. SOLUTION: A polypeptide which is coupled to albumin or its variant and contains an active moiety derived from a therapeutically active polypeptide is provided. The active moiety is a polypeptide having such a structure as to have therapeutic activity derived from the whole peptide structure by the whole peptide structure or structural modification (the mutation, substitution, addition and/or deletion of at least one residue). COPYRIGHT: (C)2003,JPO ...

METHODE ZUR HERSTELLUNG REKOMBINANTER PROTEINE UND DAFÜR VERWENDETE WIRTSZELLEN

HEFEPROMOTER UND SEINE VERWENDUNG

The invention relates to DNA sequences comprising all or part of the promoter of the K. lactis PGK gene or a derivative thereof, and possessing a transcriptional promoter activity. It also relates to the use of these sequences for the expression of recombinant genes. <IMAGE>

HOCHSTABILE REKOMBINANTE HEFEN FÜR DIE HERSTELLUNG VON REKOMBINANTEN PROTEINEN

NEUARTIGE, BIOLOGISCH AKTIVE POLYPEPTIDE, IHRE HERSTELLUNG UND DIESE POLYPEPTIDE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG

MODIFIZIERTE PILZZELLEN UND METHODE ZUR HERSTELLLUNG REKOMBINANTER PRODUKTE

HEFEPROMOTOR UND SEINE VERWENDUNG

HUMANES SERUM ALBUMIN, HERSTELLUNG UND VERWENDUNG

PCT No. PCT/FR93/00072 Sec. 371 Date Jul. 27, 1994 Sec. 102(e) Date Jul. 27, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15204 PCT Pub. Date Aug. 5, 1993The present invention relates to a preparation of serum-human albumin having a colorimetry index lower than 0.2 resulting from the expression, in a eukaryotic or prokaryotic host, of an exogenous DNA sequence.

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

PROBLEM TO BE SOLVED: To provide an artificial protein having biological activity for use in pharmaceuticals. SOLUTION: Provided is a polypeptide which is coupled to albumin or its variant and contains an active moiety derived from a therapeutically active polypeptide. The active moiety is a polypeptide having a whole peptide structure or a therapeutically active structure derived from the whole peptide structure by structural modification (mutation, substitution, addition and/or deletion of at least one residue). COPYRIGHT: (C)2008,JPO&INPIT ...

Fusion Polypeptides of Human Serum Albumin and a Therapeutically Active Polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

VERÄNDERTE KLUVEROMYCES HEFE IHRE HERSTELLUNG UND VERWENDUNG

Methods of treating using hormone-albumin fusion proteins

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for preparation, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing fusion polypeptides.

HEFEPROMOTER UND SEINE VERWENDUNG

VERÄNDERTE KLUYVEROMYCES HEFE IHRE HERSTELLUNG UND VERWENDUNG

Albumin-Derivate mit therapeutischer Funktion

Interferon and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

G-CSF and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Erythropoietin and albumin fusion protein, nucleic acids, and methods thereof

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Interleukin and albumin fusion protein

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

The invention includes biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for the preparation of such fusion polypeptides, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing such fusion polypeptides.

NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.

Process for preparing human serum albumen from a yeast

Microbiological process for preparing human serum albumen by culturing a yeast, particularly of the genus Kluyveromyces, modified using recombinant DNA techniques.

Patent FR2679920B1

PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST

USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES

La présente addition concerne un plasmide d'expression d'une protéine déterminée, dans les levures du genre Kluyveromyces, pouvant être obtenu à partir des plasmides pKan707 ou pCXJ1 selon le brevet principal, caractérisé en ce qu'il comporte au moins l'origine de réplication du plasmide pKD1, les séquences répétées inversées SRI du plasmide pKD1 et le gène A du plasmide pKD1 complet, ainsi que la séquence codante pour ladite protéine sous le contrôle de séquences assurant son expression dans une souche de Kluyveromyces. The present addition relates to an expression plasmid of a specific protein, in yeasts of the genus Kluyveromyces, which can be obtained from the plasmids pKan707 or pCXJ1 according to the main patent, characterized in that it comprises at least the origin of replication of the plasmid pKD1, the reverse SRI repeat sequences of the plasmid pKD1 and the gene A of the complete plasmid pKD1, as well as the coding sequence for said protein under the control of sequences ensuring its expression in a strain of Kluyveromyces.

Patent FR2678636B1

PROCEDURE FOR MICROBIOLOGICAL PREPARATION OF HUMANT SERUM ALBUMIN AND OTHER HETEROLOGICAL PROTEINS FROM YOURS.

En mikrobiologisk metode til fremstilling av humant serumalbumin og andre hetero- loge (ikke-gjær) proteiner ved dyrking av en gjær, særlig av slekten Kluyveromyces, modifisert ved bruk av rekombinant-DNA- teknikker, er beskrevet.

Yeast promoter and use thereof

DNA sequences comprising all or part of the $i(ADH4) gene promoter of $i(K.lactis) or a derivative of the latter, and having transcriptional promoter activity. The invention also concerns the use of said sequences for the expression of recombined genes.

Genetically modified fungal cell, method for producing recombinant products as well as DNA molecule and DNA fragments and their use

Modified fungal cells and method for producing recombinant products

This invention relates to improved fungal cells and methods for producing recombinant products of improved quality and in high yields. More specifically, the present invention relates to fungal cells carrying specific modifications within their DNA sequences which cause them to exhibit at least a reduced capacity for O-glycosylating homologous and/or heterologous proteins, and the use of these cells as host cells to produce high yields of recombinant products.

ALBUMINE DERIVATIVES WITH THERAPEUTIC FUNCTIONS.

UTILIZACION DE ALBUMINA COMO TRANSPORTADOR ESTABLE DE PLASMA CON UNA FUNCION TERAPEUTICA QUE ES DERIVADA DE UN RECEPTOR DE MEMBRANA. LA PRESENTE INVENCION SE EJEMPLIFICA POR LA DESCRIPCION DE NUEVOS AGENTES TERAPEUTICOS QUE SE PUEDEN USAR EN EL TRATAMIENTO DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA: MACRO-MOLECULAS COMPUESTAS DE DERIVADOS DE ALBUMINA ACOPLADOS A DERIVADOS DEL RECEPTOR CD4 TIENEN UNA AFINIDAD NORMAL O SUPERIOR PARA EL VIRUS VIH-1. USE OF ALBUMINE AS A STABLE PLASMA CONVEYOR WITH A THERAPEUTIC FUNCTION THAT IS DERIVED FROM A MEMBRANE RECEIVER. THE PRESENT INVENTION IS EXEMPLIFIED BY THE DESCRIPTION OF NEW THERAPEUTIC AGENTS THAT CAN BE USED IN THE TREATMENT OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME: MACRO-MOLECULES COMPOSED OF ALBUMIN DERIVATIVES FOR A CD4-NEAR RECEIVER, AND 1.

Yeast promoter and use thereof

DNA sequences comprising all or part of the ADH4 gene promoter of K.lactis or a derivative of the latter, and having transcriptional promoter activity. The invention also concerns the use of said sequences for the expression of recombined genes.

Patent FR2680518B1

Novel biologically active polypeptides, their preparation and a pharmaceutical composition containing them

Human serum albumin, preparation and pharmaceutical compositions

PCT No. PCT/FR93/00072 Sec. 371 Date Jul. 27, 1994 Sec. 102(e) Date Jul. 27, 1994 PCT Filed Jan. 26, 1993 PCT Pub. No. WO93/15204 PCT Pub. Date Aug. 5, 1993The present invention relates to a preparation of serum-human albumin having a colorimetry index lower than 0.2 resulting from the expression, in a eukaryotic or prokaryotic host, of an exogenous DNA sequence.

Albumin derivatives with therapeutic effects

Antithrombotic polypeptides as antagonists of the binding of vwf to platelets or to subendothelium

Recombinant polypeptides consisting of an adhesive portion derived from the structure of the vWF which is at least partially antagonistic to the bond between said vWF and the platelets and/or the subendothelium, as well as a portion for stabilising and presenting it $i(in vivo); preparation thereof; and pharmaceutical compositions containing said polypeptides.

Modified fungal cells and method for producing recombinant products

This invention relates to improved fungal cells and methods for producing recombinant products of improved quality and in high yields. More specifically, the present invention relates to fungal cells carrying specific modifications within their DNA sequences which cause them to exhibit at least a reduced capacity for O-glycosylating homologous and/or heterologous proteins, and the use of these cells as host cells to produce high yields of recombinant products.

Process for producing albumin derivatives and pharmaceutical compositions comprising same

A találmány tárgya albűmin alkalmazása stabil plazmatranszpőrterkéntegy őlyan terápiás fűnkcióval együtt, amely egy membránreceptőrbólszármazik. A jelen találmányban példaként egy új teráp ás ágenst írnakle, amelyet az AIDS kezelésében lehet alkalmazni: őlyan hibridmakrőmőlekűlák, amelyek albűminszármazékőkból és hőzzájűk kapcsőlt, aHIV–1 vírűshőz nőrmális vagy magas affinitással re delkező CD4-receptőrszármazékőkból állnak. ŕ

DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION

Highly stable recombinant yeast fungi for the production of recombinant proteins

Highly stable recombinant yeasts for the production of recombinant proteins

Novel recombinant yeasts are disclosed which are highly stable in a complex medium. Said yeasts are of the Kluyveromyces genus in which an essential gene is nonfunctional, containing a vector bearing a functional copy of said gene.

Yeast with modified permeability

The present invention relates to a modified yeast wherein at least two of the genes controlling the cellular permeability of said yeast are modified, said modifications having an additive or synergic effect. It also relates to a method for the preparation of said yeast as well as to its utilizations.

Modified fungal cells and method for producing recombinant products

This invention relates to improved fungal cells and methods for producing recombinant products of improved quality and in high yields. More specifically, the present invention relates to fungal cells carrying specific modifications within their DNA sequences which cause them to exhibit at least a reduced capacity for O-glycosylating homologous and/or heterologous proteins, and the use of these cells as host cells to produce high yields of recombinant products.

PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM ALBUMIN AND OTHER HETEROLOGICAL PROTEINS FROM YEAST

YEAST WITH MODIFIED PERMEABILITY

USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES

Yeast promoter and use thereof

The invention relates to DNA sequences comprising all or a portion of the promoter of the K.lactis ADH4 gene or of a derivative thereof, and possessing a transcriptional promoter activity. It also relates to the use of these sequences for the expression of recombinant genes. <IMAGE>

Fusion Polypeptides of Human Serum Albumin and a Therapeutically Active Polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Modified Kluyveromyces yeast, its preparation and use

Gjær av slekten Kluyveromyces som oppviser en eller flere genetiske modifikasjoner av minst et gen som koder for en protease, som reduserer eller modifiserer den proteolytiske aktivitet i gjærene, samt deres anvendelse som vertscelle for sekresjon av rekomblnante proteiner.

Yeast promoter and use thereof

The invention relates to DNA sequences comprising all or part of the promoter of the K. lactis PGK gene or a derivative thereof, and possessing a transcriptional promoter activity. It also relates to the use of these sequences for the expression of recombinant genes. <IMAGE>

Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides

New recombinant polypeptides (I) comprise an active portion derived from a therapeutically active polypeptide (II), genetically coupled to an albumin or albumin variant. Also claimed are: (1) a nucleotide sequence coding for (I); (2) an expression cassette comprising a sequence (1) under the control of a transcription initiation region and opt. a transcription termination region; (3) a self-replicating plasmid contg. a cassette (2); and (4) a recombinant eukaryotic or prokaryotic cell contg. a sequence (1), cassette (2) or plasmid (3).

Fusion polypeptides of human serum albumin and a therapeutically active polypeptide

Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

Stable recombinant yeasts useful for the production of recombinant proteins,their preparation and their use

Modifizierte pilzzellen und methode zur herstelllung rekombinanter produkte

Albumin-derivate mit therapeutischer funktion

Hochstabile rekombinante hefen für die herstellung von rekombinanten proteinen

Hefe mit geanderter permeabilität

Methode zur herstellung rekombinanter proteine und dafür verwendete wirtszellen

Neuartige, biologisch aktive polypeptide, ihre herstellung und diese polypeptide enthaltende pharmazeutische zusammensetzung

Humanes serum albumin, herstellung und verwendung

Hefepromotor und seine verwendung

Gj{rpromoter og dens anvendeise

DNA-sekvenser inkludert hele eller en del av promoteren av PGK-genet av K.lactls eller et derivat derav, med transkripsjonen promoter-aktivitet. Sekvensene kan benyttes for eksprimering av rekombi- nante gener.

Gjaerpromoter og dens anvendeise

Yeast promoter and its use

The invention relates to DNA sequences comprising all or part of the promoter of the K. lactis PGK gene or a derivative thereof, and possessing a transcriptional promoter activity. It also relates to the use of these sequences for the expression of recombinant genes. <IMAGE>

Hefepromoter und seine verwendung

Veränderte kluveromyces hefe ihre herstellung und verwendung